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Background: Sarcomatoid urothelial carcinoma (SUC) is a rare malignant neoplasm of the urinary bladder
comprising 0.2–0.6 % of all histological bladder tumor subtypes. It presents as a high-stage malignancy and exhibits
aggressive biological behavior, regardless of the treatment employed. It is defined as histologically indistinguishable
from sarcoma and as a high-grade biphasic neoplasm with malignant epithelial and mesenchymal components.
The mean age of patients presenting with SUC is 66 years, and the male-to-female ratio is 3:1. In addition, gross
hematuria is usually present. The prognosis of SUC is poorer than that of typical urothelial carcinoma because of
uncertainty concerning the optimal treatment regimen.
Case presentation: We report the case of a 77-year-old woman with SUC containing a chondrosarcoma
component who, 12 years previously, had undergone a nephroureterectomy for pT3N0M0 ureter cancer of the
contralateral upper urinary tract. From the 4th year of follow-up after nephroureterectomy, multiple recurrent
bladder tumors staged as Ta transitional cell carcinoma developed, and six transurethral resections of the bladder
(TURB) with multiple intravesical instillations were performed without any evidence of metastases and upper tract
recurrences. In 2015, a right partial distal ureterectomy and an additional TURB were performed due to a papillary
mass at the right contralateral ureterovesical junction of the bladder, which was confirmed as a high-grade pT1
transitional cell carcinoma. After a further 2 years of follow-up, total pelvic exenteration with an ileal conduit
diversion was performed to remove the mass, which was a pT4N0M0 tumor composed of carcinomatous and
sarcomatous elements compatible with a sarcomatoid carcinoma including grade 3 transitional cell carcinoma and
chondrosarcoma. Immunohistochemical examination showed that tumor cells were positive for vimentin and p63
and negative for NSE and Cd56 markers. In the first postoperative month, a metastatic lung nodule was detected
on chest CT. The patient was scheduled for adjuvant gemcitabine-cisplatin chemotherapy.
Conclusions: The present case was interesting because we cannot be sure if the SUC chondrosarcoma originated
from the 12-year-ago proximal ureter tumor, the 2-year-ago contralateral distal ureter tumor, or a new primary
bladder tumor. Genetic profiling might have been useful to determine the origin of the SUC chondrosarcoma.
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Fig. 1 Preoperative gynecologic MRI and abdominal CT images. a A
4-cm recurred tumor involving the bladder neck, urethra, and upper
vagina (horizontal view, abdominal pelvis CT). b An increased recurred
tumor involving the bladder neck, urethra, and upper vagina (4.6 cm).
There were no newly appearing lesions in the pelvic cavity indicating a
lack of metastasis (sagittal view, MRI gynecology). c. A 4-cm recurred
tumor involving the bladder neck, urethra, and upper vagina. There
were no other newly appearing lesions in abdominopelvic cavity
indicating a lack of metastasis (horizontal view, MRI gynecology)
Cho et al. World Journal of Surgical Oncology  (2016) 14:270 Page 2 of 4Background
Sarcomatoid urothelial carcinoma (SUC) is a rare malig-
nant neoplasm of the urinary bladder comprising 0.2–0.6 %
of all histological bladder tumor subtypes [1, 2]. It presents
as a high-stage malignancy and exhibits aggressive bio-
logical behavior, regardless of the treatment employed. It is
defined as histologically indistinguishable from sarcoma
and as a high-grade biphasic neoplasm with malignant
epithelial and mesenchymal components. In the past, when
SUC showed specific mesenchymal differentiation such as
that in chondrosarcoma, some pathologists have preferred
to use the term “carcinosarcoma” [3]. The mean age of
patients presenting with SUC is 66 years, and the male-to-
female ratio is 3:1. In addition, gross hematuria is usually
present. The prognosis of SUC is poorer than that of typical
urothelial carcinoma because of uncertainty concerning the
optimal treatment regimen.
Here, we report the case of a 77-year-old woman with
SUC containing a chondrosarcoma component who,
12 years previously, had undergone a nephroureterect-
omy for pT3N0M0 transitional cell carcinoma of ureter
cancer of the contralateral upper urinary tract.
Case presentation
A 77-year-old woman visited our hospital for multiple
recurred bladder tumors. She had a history of well-
controlled hypertension. Twelve years previously, at a
different hospital, she underwent a left nephroureterect-
omy with adjuvant chemotherapy (6 cycles of monthly
Gemzar-cisplatin combination chemotherapy and 3 cycles
of monthly Gemzar-carboplatin chemotherapy) for
pT3N0M0 poorly differentiated UC of the ureter. No
further recurrence was detected during the routine
follow-ups. On the 4th year of follow-up after nephroure-
terectomy, she developed gross hematuria and left lower
quadrant discomfort that had persisted for 2 months. She
was referred to our institution after cystoscopy revealed
multiple recurred papillary bladder tumors. Transurethral
resection of the bladder tumors (TURB) was performed
followed by 6 cycles of intravesical instillation therapy.
Histologically, the tumor was a high-grade pTa transi-
tional cell carcinoma (TCC). During the next 6 years, a
further five TURB operations were performed for recurred
bladder tumors, and three different courses of postopera-
tive intravesical instillations using mitomycin-C, epirubi-
cin, or BCG agents were performed after each TURB.
Pathologically, the tumors were low- to high-grade pTa
TCC with or without carcinoma in situ. In 2015, a gross
hematuria developed, and routine cystoscopy follow-up
revealed a papillary mass appearing at the right contralat-
eral ureterovesical junction of the bladder. Computed
tomography (CT) did not reveal any metastases or
lymph node enlargements. She underwent a right,
1.5-cm length, partial, distal ureterectomy and anend-to-end ureteroureterostomy with an additional
TURB at the right ureteral orifice. Frozen section
analysis and final pathology confirmed that the distal
and proximal ureteral margins and the resected blad-
der sections were negative for tumor cells. The mass
was confirmed as a high-grade pT1 TCC. After a
further 2 years of follow-up, CT revealed a 4-cm,
submucosal, invasive, non-pedunculated, elevated
bladder mass with an intact mucosa involving the
Fig. 2 Representative photomicrographs of the urothelial carcinoma in the bladder. a Sectional gross photograph of the specimen. The upper
part shows the bladder and the lower part shows the vagina. There is a well-demarcated round mass under the bladder mucosa. b Photomicrograph
of the TURB (×40). A poorly differentiated urothelial carcinoma is noted on the mucosa and in the subepithelial connective tissue. c A poorly differentiated
urothelial carcinoma surrounded by a sarcomatoid component (center, chondrosarcoma; ×40). d High-powered view of the chondrosarcoma component
(hematoxylin and eosin staining; ×100)
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Total pelvic exenteration with an ileal conduit diver-
sion was performed to remove the mass, which was a
pT4N0M0 tumor composed of carcinomatous and
sarcomatous elements compatible with a sarcomatoid
carcinoma including grade 3 TCC and chondrosar-
coma (Fig. 2). Immunohistochemical examination
showed that tumor cells were positive for vimentin
and p63 and negative for NSE and Cd56 markers. In
the first postoperative month, a metastatic lung nod-
ule was detected on chest CT. The patient underwent
two more cycles of adjuvant Gemzar-cisplatin chemo-
therapy, but further chemotherapy was not performed
because of her poor general condition and neutro-
penic side effects.
Discussion
SUC is an unusual malignancy containing both carcin-
omatous and sarcomatous components. It is a rare, but
aggressive, bladder cancer, comprising <1 % of all blad-
der cancers [2]. In most reported SUC cases, the epithe-
lial component was UC, although squamous cell and
small-cell carcinoma components have been reported.
The mesenchymal component varies from homogeneous
sarcoma to heterotopic elements, such as malignant
bone, cartilage, and other mesenchymal tissues. Radi-
ation and intravesical cyclophosphamide instillation
therapy are typical risk factors. In addition, a recent
multicenter study showed that 50–79 % of patients withSUC were current smokers [2]. Nodal and visceral
metastases are often present at diagnosis (>20 % of
patients). However, the present case did not present with
any of these risk factors.
A multimodal approach that includes definitive
surgery, local radiation therapy, and chemotherapy is
often used for locally advanced disease. For patients with
sarcomatoid carcinoma of the bladder, previous studies
and reviews have indicated that a GC-based regimen is
well tolerated and effective, given its ability to induce
complete remission [2–5]. Chemotherapy, therefore, has
been the mainstay treatment for metastatic disease;
however, the response rates have been varied. The 5-year
cancer-specific survival after cystectomy is 20 %, and the
median overall survival is 14 months. SUC tends to
present at an advanced stage and is associated with a
poor prognosis.
According to the WHO classification [4], macroscop-
ically, sarcomatoid carcinomas are large and polypoid
with infiltrative margins, a fleshy appearance, and the
presence of hemorrhage, necrosis, and cavitation. Micro-
scopically, conventional urothelial, squamous, glandular,
or small-cell components may be mixed with sarcomatous
components that usually predominate. The sarcomatoid
component consists of high-grade spindle-shaped or pleo-
morphic cells. Heterologous components can include
osteocarcinoma, chondrosarcoma, rhabdomyosarcoma,
leiomyosarcoma, liposarcoma, and angiosarcoma [4]. Pre-
vious studies have suggested that patients whose tumors
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compared to those without them. In 80 % of cases, epithe-
lial cells are vimentin positive, which is congruent with
the findings in the present case. Conversely, the sarcoma-
toid component can retain focal expression of high
molecular weight cytokeratins, p63, and GATA3.
The histogenesis of SUC is unclear, and Armstrong
et al. [5] examined TP53 mutation status and p53 pro-
tein expression in both the sarcomatoid and epithelial
components of SUC. They suggested a common clonal
origin of the phenotypically different tumor components,
and that TP53 mutations probably occurred early in the
common tumorigenesis of these morphologically distinct
tumor components. Subsequently, these lesions were
likely exposed to additional stimuli, giving rise to the
biphasic phenotype [5].
The present case was interesting because the patient
had a history of both high-stage pT3 ureter cancer and
contralateral distal ureter tumor. After several endo-
scopic resections for superficial low-grade recurrent
bladder tumors and intravesical instillation therapies
with multiple agents, SUC chondrosarcoma occurred in
the bladder after cystectomy. We cannot be sure if the
SUC chondrosarcoma originated from the proximal
ureter tumor that occurred 12 years earlier, the contra-
lateral distal ureter tumor that occurred 2 years earlier,
or a new primary bladder tumor. Genetic profiling might
have been useful to determine the origin of the SUC
chondrosarcoma. However, the patient was diagnosed
with metastatic lung cancer during the follow-up and
was scheduled to undergo chemotherapy.
Conclusions
We reported the case of a 77-year-old woman with SUC
containing a chondrosarcoma component. Further accu-
mulated cases studies with genetic profiling would
improve the understanding of SUC and enable optimal
treatment planning.
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